Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pathology of COPD
- Air trapping in COPD
- New bronchodilators
- Human small airways: beta2-agonists
- Indacterol vs. salmeterol in COPD
- LABA+LAMA combination in COPD
- Unmet needs in COPD
- Cellular mechanisms of COPD
- Treating inflammation in COPD
- Anti-TNF-alpha in COPD
- Chemokine receptor antagonists in COPD
- CXCR2 antagonist in COPD
- Elastase activity of macrophages in COPD
- Effect of MMP9 inhibitor on emphysema
- Broad spectrum anti-inflammatory treatment
- PDE4 inhibitors in COPD
- Effect of roflumilast in COPD
- PDE4 inhibitors: side effects
- Inhaled PDE inhibitors for COPD
- p38 MAP kinase inhibitors
- p38 MAP kinase inhibitors in COPD
- Major barrier to effective treatment of COPD
- Amplification and steroid resistance
- Corticosteroids resistance in COPD
- Theophylline as HDAC activator
- How does theophylline restore HDAC?
- Reversal of corticosteroid resistance
- Nrf2 and antioxidant gene regulation
- Sulforaphane increases HDAC2 activity
- New drugs for COPD
Topics Covered
- New treatments for COPD include long-acting bronchodilators and combinations
- Mediator antagonists, including chemokine antagonists
- Broad-spectrum anti-inflammatory treatments
- Reversal of corticosteroid resistance by increasing HDAC2
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Barnes, P. (2012, July 31). New pharmacological therapies for COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/YJZL7901.Export Citation (RIS)
Publication History
Financial Disclosures
- Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.